Improvement of Signs and Symptoms of Nonradiographic Axial Spondyloarthritis in Patients Treated With Secukinumab: Primary Results of a Randomized, Placebo-Controlled Phase III Study.
Atul A DeodharRicardo BlancoEva DokoupilováStephen HallHideto KamedaAlan J KivitzDenis PoddubnyyMarleen van de SandeAnna S WikstenBrian O PorterHanno B RichardsSibylle HaemmerleJürgen BraunPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2020)
Our findings indicate that secukinumab 150 mg provides significant and sustained improvement in signs and symptoms of nonradiographic axial SpA through 52 weeks. Safety was consistent with previous reports.
Keyphrases
- phase iii
- ankylosing spondylitis
- placebo controlled
- double blind
- open label
- clinical trial
- phase ii
- disease activity
- rheumatoid arthritis
- study protocol
- randomized controlled trial
- phase ii study
- emergency department
- systemic lupus erythematosus
- squamous cell carcinoma
- radiation therapy
- physical activity
- locally advanced
- rectal cancer